Business Context and Reporting Period
Company: International Flavors & Fragrances Inc. (IFF)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2026
Business Overview: IFF operates in three reportable segments: Taste, Health & Biosciences, and Scent. The company is undergoing a significant strategic transformation, having divested its Pharma Solutions segment in May 2025. In May 2026, IFF announced an agreement to sell its Food Ingredients business (including the Soy Crush, Concentrates, and Lecithin businesses) to CVC Capital Partners. These disposal groups are now reported as discontinued operations.
Key Financial Metrics
| Metric (in millions, except per share) | Q2 2026 | Q2 2025 | 6M 2026 | 6M 2025 |
|---|---|---|---|---|
| Net Sales (Continuing Ops) | $1,954 | $1,919 | $3,860 | $3,969 |
| Gross Profit | $853 | $824 | $1,682 | $1,676 |
| Gross Margin | 43.7% | 42.9% | 43.6% | 42.2% |
| Operating Profit | $158 | $142 | $411 | $320 |
| Net Income (Continuing Ops) | $33 | $550 | $188 | $618 |
| Net Income (Total) | $51 | $599 | $221 | $(418) |
| Diluted EPS (Total) | $0.20 | $2.33 | $0.85 | $(1.63) |
| Operating Cash Flow (6M) | $679 (2026) vs $368 (2025) | |||
| Cash & Equivalents | $569 (as of June 30, 2026) | |||
| Total Debt | $5,699 (as of June 30, 2026) |
Material Changes vs. Prior Period
- Revenue: Q2 2026 sales increased 2% ($35M) year-over-year, driven by a 6% increase on a comparable currency-neutral basis. The 6-month sales decreased 3% primarily due to the exclusion of the divested Pharma Solutions segment in 2026.
- Profitability: Operating profit increased 11% in Q2 and 28% for the six months ended June 30, 2026. This improvement is attributed to volume growth, productivity gains, and tariff refunds, offset by higher regulatory costs.
- Discontinued Operations: The prior year (2025) results included a significant loss from discontinued operations ($1.036B for 6M) due to the divestiture of Pharma Solutions and goodwill impairments. In 2026, discontinued operations generated a net income of $33M for the six months, reflecting the sale of the Soy Crush, Concentrates, and Lecithin (SCL) business.
- One-Time Items: Q2 2025 included a $488M gain on debt extinguishment and $111M in losses on business disposals, which are absent in the 2026 period. Q2 2026 included a $27M loss on assets classified as held for sale (CitraSource business).
- Tax Rate: The effective tax rate for Q2 2026 was 48.4%, a significant increase from the (25.6)% benefit in Q2 2025, driven by non-deductible regulatory costs and changes in earnings mix.
Guidance, Outlook, and Risks
- Strategic Divestitures: IFF expects to close the sale of the Food Ingredients business by the end of Q2 2027. The company will retain a 10% minority equity interest. Additionally, a portfolio of Botanical Extracts, Vitamins, and Minerals was announced for divestiture in July 2026, expected to close in Q4 2026 with an estimated pre-tax loss of $200M-$300M.
- Capital Allocation: On August 4, 2026, the Board authorized a $2.5B share repurchase program, including a $500M accelerated repurchase expected in H2 2026. The remaining $2.0B is expected to be executed after the Food Ingredients divestiture closes.
- Regulatory Risks: The company faces ongoing antitrust investigations in the EU, UK, Switzerland, Mexico, Singapore, and India regarding fragrance businesses. Significant provisions have been recorded for U.S. class action settlements ($43M in 2025, with additional settlements in 2026).
- Financial Outlook: Management expects capital spending in 2026 to be approximately 6.0% of total sales. The company remains compliant with debt covenants, with a net debt to credit-adjusted EBITDA ratio of 2.51x as of June 30, 2026.
Investor Verification Checklist
- Divestiture Timing: Verify the closing date and final proceeds of the Food Ingredients sale to CVC Capital Partners, as this impacts future revenue and cash flow.
- Regulatory Provisions: Monitor updates on antitrust investigations and potential additional fines or settlements beyond the recorded provisions.
- Discontinued Operations: Confirm the final accounting treatment and tax implications of the Food Ingredients and SCL disposal groups.
- Share Repurchase Execution: Track the execution of the $2.5B repurchase program, particularly the $500M accelerated portion.
- Tariff Refunds: Assess the realization of the $18M in tariff refunds recorded and potential for additional refunds following the Supreme Court ruling on IEEPA tariffs.